Transgene (Paris:TNG), a biotech company that designs and develops
virus-based immunotherapies against cancers and infectious diseases,
announces that new clinical data on the oncolytic virus Pexa-Vec will be
presented at the American Society for Clinical Oncology (ASCO) Annual
Meeting, taking place from 1 to 5 June in Chicago.
These results were obtained from a clinical ("neoadjuvant”) study
that evaluated the biological effects of pre-operative intravenous (IV)
administration of Pexa-Vec in patients with locally advanced or
metastatic cancers, prior to planned surgical resection. University of
Leeds (United Kingdom) is the sponsor of this trial that was supported
Single intravenous preoperative
administration of the oncolytic virus Pexa-Vec to prime anti-tumor
Session Title: Developmental therapeutics - Immunotherapy
Poster and abstract number: 3092
Date, time, location: June 4, 8:00 AM-11:30 AM, Hall A
Presenter: Dr. Alan Anthoney, University of Leeds
The abstract is now available on the ASCO website (http://abstracts.asco.org/).
- End -
Notes to editors
Pexa-Vec (JX594) is an oncolytic
immunotherapeutic based on an oncolytic vaccinia virus armed with a
GM-CSF gene that promotes an anti-tumor immune response. Pexa-Vec is
designed to selectively target and destroy cancer cells through three
different mechanisms of action: selectively destroy cancer cells through
the direct lysis (breakdown) of cancer cells through viral replication,
reduce the blood supply to tumors through vascular disruption, and
stimulate the body’s immune response against cancer cells.
is currently being evaluated in a Phase 3 trial in hepatocellular
carcinoma (HCC, liver cancer) in combination with sorafenib (current
standard of care). Other trials evaluating the oncolytic virus in solid
tumors are underway and expected to readout in 2018, including a Phase 2
trial in combination with nivolumab (HCC).
Transgene has exclusive
rights to develop and commercialize Pexa-Vec for the treatment of solid
tumors in Europe. Its partner SillaJen, Inc. is focused on developing
Pexa-Vec for the North American market and has also granted exclusive
development and commercial rights to Pexa-Vec in Hong Kong and The
People’s Republic of China to Lee’s Pharmaceutical.
Transgene (Euronext: TNG), part of
Institut Mérieux, is a publicly traded French biotechnology company
focused on designing and developing targeted immunotherapies for the
treatment of cancer and infectious diseases. Transgene’s programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s lead clinical-stage
programs are: TG4010, a therapeutic vaccine against non-small cell lung
cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a
therapeutic vaccine against HPV-positive head and neck cancers. The
Company has several other programs in clinical development, including
TG1050 (chronic hepatitis B) and TG6002 (solid tumors).
proprietary Invir.IOTM, Transgene builds on its expertise in
viral vectors engineering to design a new generation of multifunctional
Transgene is based in Strasbourg, France, and
has additional operations in Lyon, as well as a joint venture in China.
Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
This press release contains
forward-looking statements, which are subject to numerous risks and
uncertainties, which could cause actual results to differ materially
from those anticipated. There can be no guarantee that (i) the results
of pre-clinical work and prior clinical trials will be predictive of the
results of the clinical trials currently underway, (ii) regulatory
authorities will agree with the Company’s further development plans for
its therapies, or (iii) the Company will find development and
commercialization partners for its therapies in a timely manner and on
satisfactory terms and conditions, if at all. The occurrence of any of
these risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results and development.
a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to
differ from those contained in the forward-looking statements, please
refer to the Risk Factors ("Facteurs de Risques”) section of the
Document de Référence, available on the AMF website (http://www.amf-france.org)
or on Transgene’s website (www.transgene.fr).
Forward-looking statements speak only as of the date on which they are
made, and Transgene undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005952/en/